<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02399995</url>
  </required_header>
  <id_info>
    <org_study_id>15-057</org_study_id>
    <nct_id>NCT02399995</nct_id>
  </id_info>
  <brief_title>Health Related Quality of Life Following Hepatectomy for Colorectal Liver Metastasis: Global and Disease Specific Changes Over Time</brief_title>
  <official_title>Health Related Quality of Life Following Hepatectomy for Colorectal Liver Metastasis: Global and Disease Specific Changes Over Time</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Memorial Sloan Kettering Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Memorial Sloan Kettering Cancer Center</source>
  <brief_summary>
    <textblock>
      This study is being done to learn more about health related quality of life factors in people&#xD;
      having surgery for colorectal liver metastasis. The investigators will look at how these&#xD;
      factors may change over time. The information gained from this study will help the&#xD;
      investigators to understand the long-term effects that cancer treatments have on the health&#xD;
      related quality of life of patients. This information is of high value and will help doctors&#xD;
      talk to patients about the possible effects of their operations. While many patients live a&#xD;
      long time after such operations, the studies that have been done do not tell the full story&#xD;
      of what patients go through after surgery. This study will help us to understand cancer&#xD;
      treatment from the patient's perspective. It will also help cancer patients make better&#xD;
      decisions about their treatment options and will help them know what to expect after the&#xD;
      operation.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 2015</start_date>
  <completion_date type="Anticipated">March 2022</completion_date>
  <primary_completion_date type="Anticipated">March 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>changes in the quality of life (QoL)</measure>
    <time_frame>3 years</time_frame>
    <description>in patients at high risk of recurrence undergoing hepatectomy to assess health related quality of life (HRQoL) using the EORTC QLQ-C30, QLQ-LMC21 and the EuroQol EQ-5D-5L, in patients at high risk of recurrence undergoing hepatectomy for colorectal liver metastasis and to evaluate global and disease specific changes over time.</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">325</enrollment>
  <condition>Colorectal Liver Metastasis</condition>
  <arm_group>
    <arm_group_label>patients following hepatectomy</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>HRQoL questionnaires.</intervention_name>
    <description>Questionnaires/Forms to be completed preoperatively in clinic with assistance from research study administrator:&#xD;
Baseline sociodemographic and clinical variable data sheet (RSA)&#xD;
EORTC QLQ-C30, QLQ-LMC21, EuroQoL EQ-5D-5L/VAS&#xD;
Baseline disease status and treatment assessment questionnaire Questionnaires/Forms to be completed at first postoperative clinic visit:&#xD;
EORTC QLQ-C30, QLQ-LMC21, EuroQoL EQ-5D-5L/VAS&#xD;
Questionnaires/Forms to be mailed to patients at Â± 2 month window at the following time points 6,12,18,24, and 36 months following hepatectomy:&#xD;
EORTC QLQ-C30, QLQ-LMC21, EuroQoL EQ-5D-5L/VAS&#xD;
Post surgical follow up disease status and treatment assessment questionnaire&#xD;
At 8 weeks following the mailing of the initial questionnaire package if no response has been received, research personnel will attempt to contact participants by phone.</description>
    <arm_group_label>patients following hepatectomy</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        All patients scheduled to undergo liver resection who meet the established criteria will be&#xD;
        approached for participation in this study during their preoperative visit. Should patients&#xD;
        not undergo their liver resection surgery within 30 days of consent they will be excluded&#xD;
        and replaced. Patients undergoing a two stage resection will have their time point frozen&#xD;
        for up to six months after their initial surgery. If the time before the second stage of&#xD;
        their resection exceeds six months, these patients will be excluded and replaced. The time&#xD;
        point will restart at the completion of the second time point. If the patient has an&#xD;
        incomplete resection without mention of a second stage resection, the patient will be made&#xD;
        ineligible, taken off study, and replaced.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of Colorectal cancer liver metastases (CRLM)&#xD;
&#xD;
          -  &gt; 18 years of age&#xD;
&#xD;
          -  Absence of unresectable extrahepatic disease&#xD;
&#xD;
          -  No previous liver surgery for CRLM&#xD;
&#xD;
          -  Clinical risk score (CRS) &gt;/= 3 or &gt; 4 tumors&#xD;
&#xD;
          -  CRS includes the following variables;&#xD;
&#xD;
          -  Lymph node positive primary&#xD;
&#xD;
          -  Disease free interval &lt;12 months&#xD;
&#xD;
          -  CEA level &gt;200ng/mL (highest CEA level within 6 months prior to surgery, not including&#xD;
             day of surgery)&#xD;
&#xD;
          -  Tumor size &gt; 5cm&#xD;
&#xD;
          -  Number of tumors &gt;1(based on most recent scan or pathology before liver resection)&#xD;
&#xD;
          -  Each variable is given a score of one and summed to give final CRS&#xD;
&#xD;
          -  Clinical risk score (CRS) &lt; 3 with pending variables that cannot be determined&#xD;
             preoperatively&#xD;
&#xD;
          -  If CRS is still &lt; 3 postoperatively, these patients will be excluded and replaced&#xD;
             (inevaluable).&#xD;
&#xD;
          -  Ability to read and write in English&#xD;
&#xD;
          -  Undergoing liver resection/ ablation for CRLM&#xD;
&#xD;
          -  Underwent liver resection/ ablation for CRLM, but not their primary tumors&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Non-English speaking&#xD;
&#xD;
          -  Inability to read and/or write&#xD;
&#xD;
          -  International Patients&#xD;
&#xD;
          -  Concurrent malignancy (excluding non-melanoma skin cancers)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael D'Angelica, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Memorial Sloan Kettering Cancer Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Michael D'Angelica, MD</last_name>
    <phone>212-639-3226</phone>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Raymond Baser, MD</last_name>
    <phone>646-888-8294</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Basking Ridge (Consent and Follow up)</name>
      <address>
        <city>Basking Ridge</city>
        <state>New Jersey</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael D'Angelica</last_name>
      <phone>212-639-3226</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Monmouth (Consent and Follow up)</name>
      <address>
        <city>Middletown</city>
        <state>New Jersey</state>
        <zip>07748</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael D'Angelica, MD</last_name>
      <phone>212-639-3226</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Bergen (Consent and Follow up)</name>
      <address>
        <city>Montvale</city>
        <state>New Jersey</state>
        <zip>07645</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael D'Angelica, MD</last_name>
      <phone>212-639-3226</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Commack (Consent and Follow up)</name>
      <address>
        <city>Commack</city>
        <state>New York</state>
        <zip>11725</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael D'Angelica, MD</last_name>
      <phone>212-639-3226</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Westchester (Consent and Follow Up)</name>
      <address>
        <city>Harrison</city>
        <state>New York</state>
        <zip>10604</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael D'Angelica, MD</last_name>
      <phone>212-639-3226</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center (All Protocol Activities)</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael D'Angelica, MD</last_name>
      <phone>212-639-3226</phone>
    </contact>
    <contact_backup>
      <last_name>Raymond Baser, MD</last_name>
      <phone>646-888-8294</phone>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Nassau (Consent and follow up)</name>
      <address>
        <city>Uniondale</city>
        <state>New York</state>
        <zip>11553</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael D'Angelica, MD</last_name>
      <phone>212-639-3226</phone>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mskcc.org/</url>
    <description>Memorial Sloan Kettering Cancer Center</description>
  </link>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>March 23, 2015</study_first_submitted>
  <study_first_submitted_qc>March 23, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 26, 2015</study_first_posted>
  <last_update_submitted>April 1, 2021</last_update_submitted>
  <last_update_submitted_qc>April 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Quality of Life</keyword>
  <keyword>Hepatectomy</keyword>
  <keyword>15-057</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Liver Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

